⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13720541 | 0.51 | — | — | |
| SCHEMBL3211853 | 0.51 | — | — | |
| SCHEMBL6902250 | 0.48 | — | — | |
| SCHEMBL246873 | 0.48 | — | — | |
| SCHEMBL5634359 | 0.48 | — | — | |
| SCHEMBL18285616 | 0.42 | — | — | |
| SCHEMBL905165 | 0.42 | — | — | |
| SCHEMBL1351735 | 0.40 | — | — | |
| SCHEMBL1819677 | 0.40 | — | — | |
| SCHEMBL369355 | 0.40 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301280-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20180072722-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Bio SA (CH) | 2018-03-15 | — | — | US | disclosed |
| US-9856259-B2 | Heterocyclic compounds and uses thereof | PLEXXIKON INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170349572-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-12-07 | — | — | US | disclosed |
| US-9822109-B2 | Heterocyclic compounds and uses thereof | PLEXXIKON INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20170320899-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PLEXXIKON INC. (US) | 2017-11-09 | — | — | US | disclosed |
| US-9718847-B2 | Heterocyclic compounds and uses thereof | PLEXXIKON INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9676748-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9353100-B2 | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections | IDENIX PHARMACEUTICALS LLC (US) | 2016-05-31 | — | — | US | disclosed |
| US-20160068528-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Bio SA (CH) | 2016-03-10 | — | — | US | disclosed |
| CN-105308036-A | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC | 2016-02-03 | — | — | CN | disclosed |
| CN-105073747-A | Heterocyclic compounds and their use | PLEXXIKON INC | 2015-11-18 | — | — | CN | disclosed |
| US-20150133400-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Bio SA (CH) | 2015-05-14 | — | — | US | disclosed |
| US-20140303121-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PLEXXIKON INC. | 2014-10-09 | — | — | US | disclosed |
| US-20140213554-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-07-31 | — | — | US | disclosed |
| WO-2012109398-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE FOR TREATING HCV INFECTIONS | IDENIX PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | WO | disclosed |
| US-20120207703-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE FOR TREATING HCV INFECTIONS | IDENIX PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20080312207-A1 | Compounds | SYNGENTA CROP PROTECTION AG (CH) | 2008-12-18 | — | — | US | disclosed |
| EP-1718625-A1 | COMPOUNDS | AstraZeneca AB (SE) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005080360-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2005-09-01 | — | — | WO | disclosed |